title: Adoptive immunotherapy after hematopoietic stem cell transplantation.
abstract: Adoptive immunotherapy may be performed with either autologous or allogeneic lymphocytes. Autologous cellular immunotherapy is hindered by the inability to break anergy or self-tolerance. Advances in this area have focused on the use of tumor-specific lymphocytes activated by antigen-pulsed or transgene modified dendritic cells. Allogeneic cellular immunotherapy is effective even with the use of non-specific and unactivated donor lymphocytes. Allogeneic cellular therapy is, however, complicated by graft-versus-host disease (GVHD). Advances in allogeneic immunotherapy will require better control of GVHD.
authors.affiliation: Northwestern University Medical School, Department of Medicine, Chicago, IL 60611, USA.
authors.forename: R K
authors.initials: RK
authors.lastname: Burt
authors.forename: C
authors.initials: C
authors.lastname: Link
authors.forename: A
authors.initials: A
authors.lastname: Traynor
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016219:Immunotherapy, Adoptive; D008214:Lymphocytes / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*